Biomedical subjects

E Alhava

Publications and source records attributed to E Alhava.

220 records · Page 13Linked to original sources

PubMedDate not supplied

Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.

A prospective study of 277 patients with benign (n = 212) and malignant (n = 65) hepatopancreatobiliary disease was carried out to evaluate the value of six serum tumour markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and 16 conventional laboratory tests in the distinction between benign and malignant diseases. In univariate analysis, all tumour marker tests except TATI showed significantly (p < 0.001) higher serum values in the patients with malignant disease than in the patients with benign disease. Among the conventional laboratory tests serum bilirubin, alkaline phosphatase and leucine aminopeptidase showed significantly. (p < 0.001) higher values in the patients with malignant disease, whereas serum protein and amylase levels were significantly (p < 0.01) higher in the patients with benign disease. In a multivariate analysis, serum bilirubin (p < 0.001), antithrombin III (p < 0.01) and blood hemoglobin (p < 0.05) were the most significant independent predictors of hepatopancreatobiliary malignancy. To sum up the contributions of the best tests a diagnostic score (DS) was developed. The sensitivity of DS in detecting malignancy was 73% with a specificity of 82% and an efficiency of 79%. In conclusion, our results speak against the use of multiple tumour marker tests, and rather suggest the use of a relatively limited amount of conventional laboratory tests in the distinction between benign and malignant hepatopancreatobiliary disease.

Alkaline Phosphatase↗

PubMedDate not supplied

Comparison of classic and quantitative prognostic factors in colorectal cancer.

Despite the many pathologic and clinical variables shown to influence survival rates in patients with colorectal cancer, the prediction of outcome after curative resection is still not completely reliable. Dukes-classification has been historically the strongest prognostic indicator and the most frequently employed method. In this study our aim was to search for significant independent histological and morphometric factors that could possibly be used in predicting the outcome of different stages of colorectal cancer. We analysed the clinical follow-up data of 308 patients with colorectal adenocarcinoma (followed-up for a mean of 14.4 years). The clinical findings were correlated to histological and morphometric factors to establish their value as predictors of colorectal adenocarcinoma Clinical, histological and morphometric factors were significantly interrelated. The large invasive tumours had larger nuclei, a larger variation in nuclear size, and they were also rapidly proliferating. In univariate survival analysis Dukes, the mean nuclear area (NA), standard deviation of nuclear area (SDNA), nuclear perimetry (PE) and the mean of the longest nuclear axis (Dmax) were the most important predictors of recurrence-free survival (RFS). TNM-categories, Dukes, histological grade and all the quantitative variables were significant predictors of cancer related survival. In a multivariate analysis of Tl-4N0-3M0 tumours (n = 164) N-category, nuclear area and the vear of operation and in local tumours (Tl-2N0M0) (n = 70) Dmax and Dukes predicted RFS. Important determinants of survival in all 269 cases were M-category. Dukes and Dmax and in local tumours (Tl-2N0M0) (n = 67) Dmax. These results indicate that although an accurate prognostic evaluation of colorectal carcinomas can be based on TNM- and Dukes-classification, nuclear morphometry can give additional prognostic information.

Adult↗

PubMedDate not supplied

Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.

The aim of the present study was to assess the clinical value of five serum tumour markers AFP, CA 15-3, CEA, TPS and Neu oncoprotein (p 185) in the diagnosis of breast cancer. The serum values were measured in a prospective series of patients with breast cancer (n = 233), benign breast disease (n = 176) and healthy control subjects (n = 215). The cut-off levels (90% specificity) were determined for each test. Using these cut-off levels the diagnostic sensitivity of the CEA test was 0.23, for the AFP test it was 0.16, for the CA 15-3 test 0.27, for the TPS test 0.18 and for the Neu oncoprotein test 0.19 in detecting breast cancer. Correlation coefficients (Pearson's) were statistically significant between CEA and CA 15-3, and between CA 15-3 and Neu oncoprotein measurements in breast cancer patients. In patients with benign breast disease the serum levels of AFP, CA 15-3, CEA and TPS correlated with age, being somewhat higher in older patients. Similarly, in population controls higher age correlated with higher levels of AFP, CA 15-3, Neu and TPS. In breast cancer patients there was no correlation between the age at diagnosis and any of the measured markers. The only marker statistically significantly associated with the stage of breast cancer was CA 15-3. In conclusion, our results indicate that serum CEA, AFP, CA 15-3, TPS and Neu oncoprotein are only of limited value in the diagnosis of breast cancer.

Adult↗

PubMedDate not supplied

Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.

The expression of apoptosis suppressing protein bcl-2, tumour-suppressor protein p53, and proliferation marker Ki-67 and their possible prognostic value were analysed in pancreatic ductal adenocarcinoma. Fifty-two % (34/64) of the samples were positive for bcl-2 and immunostaining were mainly localized in the cytoplasm of tumour cells. Bcl-2 expression was not related to tumour grade, DNA ploidy or S-phase fraction or to any clinical parameters. In univariate analysis bcl-2 expression predicted favourable outcome (p = 0.008). Positive nuclear staining for p53 was found in 40% (24/59) of samples and 80% (60/74) of the tumours were positive for Ki-67. p53 and Ki-67 expressions were not related to patient survival. According to our results, bcl-2 expression seems to be a predictor of disease outcome and may have some clinical value in human pancreatic cancer.

Aged↗